- Home
- CDXS vs ACIU Comparison
CDXS vs ACIU Comparison
Compare CDXS & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDXS
- ACIU
- Stock Information
- Founded
- CDXS 2002
- ACIU 2003
- Country
- CDXS United States
- ACIU Switzerland
- Employees
- CDXS N/A
- ACIU N/A
- Industry
- CDXS Major Chemicals
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- CDXS Industrials
- ACIU Health Care
- Exchange
- CDXS Nasdaq
- ACIU Nasdaq
- Market Cap
- CDXS 201.3M
- ACIU 189.1M
- IPO Year
- CDXS 2010
- ACIU 2016
- Fundamental
- Price
- CDXS $3.04
- ACIU $2.04
- Analyst Decision
- CDXS Buy
- ACIU Strong Buy
- Analyst Count
- CDXS 2
- ACIU 1
- Target Price
- CDXS $11.00
- ACIU $12.00
- AVG Volume (30 Days)
- CDXS 910.6K
- ACIU 123.5K
- Earning Date
- CDXS 08-07-2025
- ACIU 08-05-2025
- Dividend Yield
- CDXS N/A
- ACIU N/A
- EPS Growth
- CDXS N/A
- ACIU N/A
- EPS
- CDXS N/A
- ACIU N/A
- Revenue
- CDXS $49,815,000.00
- ACIU $32,014,254.00
- Revenue This Year
- CDXS $12.77
- ACIU N/A
- Revenue Next Year
- CDXS $22.12
- ACIU $533.21
- P/E Ratio
- CDXS N/A
- ACIU N/A
- Revenue Growth
- CDXS N/A
- ACIU 91.20
- 52 Week Low
- CDXS $1.90
- ACIU $1.43
- 52 Week High
- CDXS $6.08
- ACIU $4.26
- Technical
- Relative Strength Index (RSI)
- CDXS 69.54
- ACIU 54.21
- Support Level
- CDXS $2.55
- ACIU $1.94
- Resistance Level
- CDXS $2.91
- ACIU $2.15
- Average True Range (ATR)
- CDXS 0.20
- ACIU 0.16
- MACD
- CDXS 0.06
- ACIU -0.00
- Stochastic Oscillator
- CDXS 96.17
- ACIU 72.22
About CDXS Codexis Inc.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.